Postoperative venous thromboembolism after surgery for locally recurrent rectal cancer.
Locally recurrent rectal cancer
Pharmacological prophylaxis
Sacral resection
Total pelvic exenteration
Venous thromboembolism
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
received:
02
04
2024
accepted:
13
08
2024
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
20
8
2024
Statut:
epublish
Résumé
Local recurrence is common after curative resections of rectal cancer. Surgical resection is considered a primary curative treatment option for patients with locally recurrent rectal cancer (LRRC). LRRC often requires a combined resection of other organs, especially in the case of posterior recurrence, which requires a combined resection of the sacrum, making the surgery highly invasive. Venous thromboembolism (VTE) is one of the lethal complications in the postoperative period, particularly in the field of pelvic surgery. We found no reports regarding the risks of postoperative VTE in surgery for LRRC, a typical highly invasive procedure in the field of colorectal surgery. This study aims to evaluate the risk of postoperative VTE in surgery for LRRC patients. From April 2010 to March 2022, a total of 166 patients underwent surgery for LRRC in the pelvic region at our institutions. Clinicopathological background and VTE incidence were compared retrospectively. Among the 166 patients included in the study, 55 patients (33.1%) needed sacral resection. Pharmacological prophylaxis for prevention of VTE was performed in 121 patients (73.3%), and the incidence of VTE was 9.09% (5/55 patients) among those who underwent surgery for LRRC with sacral resection, while it was 1.8% (2/111 patients) in those without sacral resection. In univariate analysis, the combination with sacral resection was identified as a risk factor for VTE in surgery for LRRC (p = 0.047). This study demonstrates that surgery for LRRC combined with sacral resection could be a significant risk factor for VTE.
Sections du résumé
BACKGROUND
BACKGROUND
Local recurrence is common after curative resections of rectal cancer. Surgical resection is considered a primary curative treatment option for patients with locally recurrent rectal cancer (LRRC). LRRC often requires a combined resection of other organs, especially in the case of posterior recurrence, which requires a combined resection of the sacrum, making the surgery highly invasive. Venous thromboembolism (VTE) is one of the lethal complications in the postoperative period, particularly in the field of pelvic surgery. We found no reports regarding the risks of postoperative VTE in surgery for LRRC, a typical highly invasive procedure in the field of colorectal surgery. This study aims to evaluate the risk of postoperative VTE in surgery for LRRC patients.
METHODS
METHODS
From April 2010 to March 2022, a total of 166 patients underwent surgery for LRRC in the pelvic region at our institutions. Clinicopathological background and VTE incidence were compared retrospectively.
RESULTS
RESULTS
Among the 166 patients included in the study, 55 patients (33.1%) needed sacral resection. Pharmacological prophylaxis for prevention of VTE was performed in 121 patients (73.3%), and the incidence of VTE was 9.09% (5/55 patients) among those who underwent surgery for LRRC with sacral resection, while it was 1.8% (2/111 patients) in those without sacral resection. In univariate analysis, the combination with sacral resection was identified as a risk factor for VTE in surgery for LRRC (p = 0.047).
CONCLUSIONS
CONCLUSIONS
This study demonstrates that surgery for LRRC combined with sacral resection could be a significant risk factor for VTE.
Identifiants
pubmed: 39164626
doi: 10.1186/s12885-024-12799-1
pii: 10.1186/s12885-024-12799-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1027Informations de copyright
© 2024. The Author(s).
Références
Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246(5):693–701.
doi: 10.1097/01.sla.0000257358.56863.ce
pubmed: 17968156
van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–82.
doi: 10.1016/S1470-2045(11)70097-3
pubmed: 21596621
Beppu N, Kimura F, Aihara T, Doi H, Tomita N, Yanagi H, et al. Patterns of local recurrence and oncologic outcomes in T3 low rectal Cancer (=5 cm from the anal verge) treated with short-course Radiotherapy with delayed surgery: outcomes in T3 low rectal Cancer treated with short-course Radiotherapy with delayed Surgery</at. Ann Surg Oncol. 2017;24(1):219–26.
doi: 10.1245/s10434-016-5604-6
pubmed: 27699610
Paku M, Uemura M, Kitakaze M, Fujino S, Ogino T, Miyoshi N, et al. Impact of the preoperative prognostic nutritional index as a predictor for postoperative complications after resection of locally recurrent rectal cancer. BMC Cancer. 2021;21(1):435.
doi: 10.1186/s12885-021-08160-5
pubmed: 33879101
pmcid: 8056720
Asoglu O, Karanlik H, Muslumanoglu M, Igci A, Emek E, Ozmen V, et al. Prognostic and predictive factors after surgical treatment for locally recurrent rectal cancer: a single institute experience. Eur J Surg Oncol. 2007;33(10):1199–206.
doi: 10.1016/j.ejso.2007.02.026
pubmed: 17400423
Uemura M, Ikeda M, Yamamoto H, Kitani K, Tokuoka M, Matsuda K, et al. Clinicopathological assessment of locally recurrent rectal cancer and relation to local re-recurrence. Ann Surg Oncol. 2011;18(4):1015–22.
doi: 10.1245/s10434-010-1435-z
pubmed: 21082358
Dresen RC, Gosens MJ, Martijn H, Nieuwenhuijzen GA, Creemers GJ, Daniels-Gooszen AW, et al. Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer. Ann Surg Oncol. 2008;15(7):1937–47.
doi: 10.1245/s10434-008-9896-z
pubmed: 18389321
pmcid: 2467498
Palmer G, Martling A, Cedermark B, Holm T. A population-based study on the management and outcome in patients with locally recurrent rectal cancer. Ann Surg Oncol. 2007;14(2):447–54.
doi: 10.1245/s10434-006-9256-9
pubmed: 17139457
Uemura M, Ikeda M, Sekimoto M, Haraguchi N, Mizushima T, Yamamoto H, et al. Prevention of severe pelvic abscess formation following extended radical surgery for locally recurrent rectal cancer. Ann Surg Oncol. 2009;16(8):2204–10.
doi: 10.1245/s10434-009-0505-6
pubmed: 19506961
Emoto S, Nozawa H, Kawai K, Hata K, Tanaka T, Shuno Y, et al. Venous thromboembolism in colorectal surgery: incidence, risk factors, and prophylaxis. Asian J Surg. 2019;42(9):863–73.
doi: 10.1016/j.asjsur.2018.12.013
pubmed: 30683604
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15273542
pmcid: 1360123
Righini M, Van Es J, Den Exter PL, Roy PM, Verschuren F, Ghuysen A, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311(11):1117–24.
doi: 10.1001/jama.2014.2135
pubmed: 24643601
McKigney N, Houston F, Ross E, Velikova G, Brown J, Harji DP. Systematic review of patient-reported outcome measures in locally recurrent rectal Cancer. Ann Surg Oncol. 2023;30(7):3969–86.
doi: 10.1245/s10434-023-13388-5
pubmed: 37071237
pmcid: 10250265
Huang Y, Steffens D, Koh CE, Young JM, Solomon MJ. Differences in Surgical outcomes and Quality-of-life outcomes in pelvic exenteration between locally Advanced Versus locally recurrent rectal cancers. Dis Colon Rectum. 2022;65(12):1475–82.
doi: 10.1097/DCR.0000000000002401
pubmed: 35913831
Hagemans JAW, van Rees JM, Alberda WJ, Rothbarth J, Nuyttens J, van Meerten E, et al. Locally recurrent rectal cancer; long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre. Eur J Surg Oncol. 2020;46(3):448–54.
doi: 10.1016/j.ejso.2019.10.037
pubmed: 31761506
Westberg K, Palmer G, Hjern F, Johansson H, Holm T, Martling A. Management and prognosis of locally recurrent rectal cancer - A national population-based study. Eur J Surg Oncol. 2018;44(1):100–7.
doi: 10.1016/j.ejso.2017.11.013
pubmed: 29224985
You YN, Roses RE, Chang GJ, Rodriguez-Bigas MA, Feig BW, Slack R, et al. Multimodality salvage of recurrent disease after local excision for rectal cancer. Dis Colon Rectum. 2012;55(12):1213–9.
doi: 10.1097/DCR.0b013e318270837f
pubmed: 23135578
Uemura M, Ikeda M, Kawai K, Nishimura J, Takemasa I, Mizushima T, et al. Laparoscopic surgery using a Gigli wire saw for locally recurrent rectal cancer with concomitant intraperitoneal sacrectomy. Asian J Endosc Surg. 2018;11(1):83–6.
doi: 10.1111/ases.12407
pubmed: 29485249
Kitakaze M, Uemura M, Kobayashi Y, Paku M, Miyo M, Takahashi Y, et al. Postoperative pain management after concomitant sacrectomy for locally recurrent rectal cancer. Surg Today. 2022;52(11):1599–606.
doi: 10.1007/s00595-022-02522-7
pubmed: 35661260
Phukan R, Herzog T, Boland PJ, Healey J, Rose P, Sim FH, et al. How does the level of Sacral Resection for primary malignant bone tumors affect physical and Mental Health, Pain, mobility, incontinence, and sexual function? Clin Orthop Relat Res. 2016;474(3):687–96.
doi: 10.1007/s11999-015-4361-3
pubmed: 26013155
Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):eS227–77.
doi: 10.1378/chest.11-2297
Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133(6 Suppl):s381-453.
doi: 10.1378/chest.08-0656
Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975–80.
doi: 10.1056/NEJMoa012385
pubmed: 11919306
Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis(JCS. 2017). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito_h.pdf . 2017.